Longitudinal characterization of herpes simplex virus (HSV) isolates acquired from different sites in an immune-compromised child: A new HSV thymidine kinase mutation associated with resistance

Journal of the Pediatric Infectious Diseases Society

Volumn 1, Issue 2, 2012, Pages 116-124

  Karaba, Andrew H ^a   Cohen, Laura K ^a   Glaubach, Taly ^a   Kopp, Sarah J ^a   Reichek, Jennifer L ^a   Yoon, Hawke H ^a   Zheng, Xiaotian T ^b   Muller, William J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FOSCARNET; THYMIDINE KINASE; TRIFLURIDINE;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CASE REPORT; CHILD; CONJUNCTIVITIS; CONTROLLED STUDY; CORNEA ULCER; DNA SEQUENCE; FEBRILE NEUTROPENIA; FEVER; GENOTYPE; HERPES SIMPLEX VIRUS 1; HERPETIC STOMATITIS; HUMAN; HUMAN CELL; IMMUNOCOMPROMISED PATIENT; MOUTH PAIN; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; THROAT CULTURE; VESICULAR RASH;

EID: 84887317484     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/pis009     Document Type: Article

References (43)

1. Schiffer JT, Corey L. Herpes simplex virus. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone, 2009: 1948.
2. Bacon TH, Levin MJ, Leary JJ, Sarisky RT, Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003; 16: 114-28.
3. Sarisky RT, Nguyen TT, Duffy KE, Wittrock RJ, Leary JJ. Difference in incidence of spontaneous mutations between herpes simplex virus types 1 and 2. Antimicrob Agents Chemother 2000; 44: 1524-9.
4. Shin YK, Cai GY, Weinberg A, Leary JJ, Levin MJ. Frequency of acyclovir-resistant herpes simplex virus in clinical specimens and laboratory isolates. J Clin Microbiol 2001; 39:913-7.
5. Coen DM. Acyclovir-resistant, pathogenic herpesviruses. Trends Microbiol 1994; 2:481-5.
6. Field HJ. Herpes simplex virus antiviral drug resistance-current trends and future prospects. J Clin Virol 2001; 21:261-9.
7. Duan R, de Vries RD, Osterhaus AD, Remeijer L, Verjans GM. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis 2008; 198:659-63.
8. Mocarski ES, Post LE, Roizman B. Molecular engineering of the herpes simplex virus genome: insertion of a second L-S junction into the genome causes additional genome inversions. Cell 1980; 22:243-55.
9. Sacks SL, Wanklin RJ, Reece DE, Hicks KA, Tyler KL, Coen DM. Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? Ann Intern Med 1989; 111:893-9.
10. Safrin S, Elbeik T, Phan L, et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1994; 38:1246-50.
11. Safrin S, Kemmerly S, Plotkin B, et al. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis 1994; 169: 193-6.
12. Burrel S, Deback C, Agut H, Boutolleau D. Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. Antimicrob Agents Chemother 2010; 54:4833-42.
13. Sauerbrei A, Deinhardt S, Zell R, Wutzler P. Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus. Antiviral Res 2010; 86:246-52.
14. Chibo D, Druce J, Sasadeusz J, Birch C. Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus. Antiviral Res 2004; 61:83-91.
15. Bestman-Smith J, Schmit I, Papadopoulou B, Boivin G. Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues. J Virol 2001; 75:3105-10.
16. Duan R, de Vries RD, van Dun JM, et al. Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis. J Infect Dis 2009; 200:1402-14.
17. Schulte EC, Sauerbrei A, Hoffmann D, Zimmer C, Hemmer B, Muhlau M. Acyclovir resistance in herpes simplex encephalitis. Ann Neurol 2010; 67:830-3.
18. Bohn K, Zell R, Schacke M, Wutzler P, Sauerbrei A. Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus. Antivir Ther 2011; 16:989-97.
19. Morfin F, Souillet G, Bilger K, Ooka T, Aymard M, Thouvenot D. Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. J Infect Dis 2000; 182:290-3.
20. Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 2011; 55:459-72.
21. Stranska R, van Loon AM, Polman M, et al. Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients. Antivir Ther 2004; 9:565-75.
22. Schmit I, Boivin G. Characterization of the DNA polymerase and thymidine kinase genesof herpes simplex virus isolates from AIDS patients in whom acyclovirand foscarnet therapy sequentially failed. J Infect Dis 1999; 180:487-90.
23. Frobert E, Ooka T, Cortay JC, Lina B, Thouvenot DMorfin F. Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study. Antimicrob Agents Chemother 2005; 49:1055-9.
24. Oram RJ, Marcellino D, Strauss D, et al. Characterization of an acyclovir-resistant herpes simplex virus type 2 strain isolated from a premature neonate. J Infect Dis 2000; 181:1458-61.
25. Levin MJ, Weinberg A, Leary JJ, Sarisky RT. Development of acyclovir-resistant herpes simplex virus early during the treatment of herpes neonatorum. Pediatr Infect Dis J 2001; 20: 1094-7.
26. Sibrack CD, Gutman LT, Wilfert CM, et al. Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. J Infect Dis 1982; 146:673-82.
27. Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003; 26:29-37.
28. Danve-Szatanek C, Aymard M, Thouvenot D, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004; 42:242-9.
29. Diamond C, Mohan K, Hobson A, Frenkel L, Corey L. Viremia in neonatal herpes simplex virus infections. Pediatr Infect Dis J 1999; 18:487-9.
30. Johnston C, Magaret A, Selke S, Remington M, Corey L, Wald A. Herpes simplex virus viremia during primary genital infection. J Infect Dis 2008; 198:31-4.
31. Juhl D, Mosel C, Nawroth F, et al. Detection of herpes simplex virus DNA in plasma of patients with primary but not with recurrent infection: implications for transfusion medicine? Transfus Med 2010; 20:38-47.
32. Kost RG, Hill EL, Tigges M, Straus SE. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med 1993; 329:1777-82.
33. Jones TJ, Paul R. Disseminated acyclovir-resistant herpes simplex virus type 2 treated successfully with foscarnet. J Infect Dis 1995; 171:508-9.
34. Safrin S. Acyclovir-resistant herpes simplex virus infection. J Infect Dis 1995; 172:603.
35. Snoeck R, Andrei G, Gerard M, et al. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC). Clin Infect Dis 1994; 18:570-8.
36. LoPresti AE, Levine JF, Munk GB, Tai CY, Mendel DB. Successful treatment of an acyclovirand foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir. Clin Infect Dis 1998; 26:512-3.
37. Dvorak CC, Cowan MJ, Horn B, Weintrub PS. Development of herpes simplex virus stomatitis during receipt of cidofovir therapy. Clin Infect Dis 2009; 49:e92-5.
38. Wyles DL, Patel A, Madinger N, Bessesen M, Krause PR, Weinberg A. Development of herpes simplex virus disease in patients who are receiving cidofovir. Clin Infect Dis 2005; 41:676-80.
39. Chen Y, Scieux C, Garrait V, et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis 2000; 31:927-35.
40. Wang Y, Wang Q, Zhu Q, Zhou R, Liu J, Peng T. Identification and characterization of acyclovirresistant clinical HSV-1 isolates from children. J Clin Virol 2011; 52:107-12.
41. Frobert E, Cortay JC, Ooka T, et al. Genotypic detection of acyclovir-resistant HSV-1: characterization of 67 ACV-sensitive and 14 ACV-resistant viruses. Antiviral Res 2008; 79:28-36.
42. Morfin F, Thouvenot D, Aymard M, Souillet G. Reactivation of acyclovir-resistant thymidine kinase-deficient herpes simplex virus harbouring single base insertion within a 7 Gs homopolymer repeat of the thymidine kinase gene. J Med Virol 2000; 62:247-50.
43. Kudo E, Shiota H, Naito T, Satake K, Itakura M. Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: analysis of clinical isolates from herpetic keratitis patients and laboratory strains. J Med Virol 1998; 56:151-8.